Connect Biopharmaceuticals’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Connect Biopharmaceuticals is a clinical-stage company that develops immune modulators for the treatment of autoimmune and inflammatory diseases. Read more

Connect Biopharmaceuticals is a clinical-stage company that develops immune modulators for the treatment of autoimmune and inflammatory diseases. Read more

Zheng Wei's photo - Co-Founder & CEO of Connect Biopharmaceuticals

Co-Founder & CEO

Zheng Wei

CEO Approval Rating

89/100

Founded:

2012

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Sino Biological is seen as one of Connect Biopharmaceuticals's top competitors. Sino Biological was founded in Beijing, Beijing Municipality} in 2007. Sino Biological is in the Biotechnology industry. Compared to Connect Biopharmaceuticals, Sino Biological generates $24.4M more revenue.

BeiGene is Connect Biopharmaceuticals's #2 competitor. BeiGene was founded in 2010, and its headquarters is in Beijing, Beijing Municipality. BeiGene competes in the Biotechnology industry. BeiGene has 4,150 more employees than Connect Biopharmaceuticals.

Innovent is Connect Biopharmaceuticals's #3 rival. Innovent is headquartered in Suzhou, Jiangsu Province, and was founded in 2011. Like Connect Biopharmaceuticals, Innovent also competes in the Biotechnology industry. Innovent generates 2,676% the revenue of Connect Biopharmaceuticals.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 50 a good estimate for Connect Biopharmaceuticals's Employee count?

Acquisitions

No recent acquisitions found related to Connect Biopharmaceuticals

Connect Biopharmaceuticals Funding History

$20M$75M$190M

Since Connect Biopharmaceuticals was founded in 2012, it has participated in 3 rounds of funding. In total Connect Biopharmaceuticals has raised $190.0M. Connect Biopharmaceuticals' last funding round was on Aug 2020 for a total of $115.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
Aug 2020
$115M

RA Capital Management

Series B
Jan 2019
$55M
Series A
Jan 2017
$20M

Total Funding: $190M

Since Connect Biopharmaceuticals was founded in 2012, it has participated in 3 rounds of funding. In total Connect Biopharmaceuticals has raised $190.0M. Connect Biopharmaceuticals' last funding round was on Aug 2020 for a total of $115.0M

Investments

No recent investments found related to Connect Biopharmaceuticals

Connect Biopharmaceuticals News

January 8, 2020BioPortfolio

Connect Biopharma Reports Positive Topline Data from Moderatetosevere Atopic Dermatitis AD Phase 1b Study of CBP201

Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP201 c... See more »
May 7, 2019BioPortfolio

Connect Bio Reports Positive Phase I Data for Atopic Dermatitis Treatment

Connect Biopharma of Suzhou completed a successful Phase I single ascending dose trial of its novel I... See more »
January 4, 2019BioPortfolio

Connect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies

Connect Biopharma a clinicalstage Suzhou company completed a $55 million Series B financing to suppor... See more »
January 3, 2019Asian Venture Capital Journal

Advantech leads $55m round for China biotech player

Advantech Capital has led a $55 million Series B funding round for China's Connect Biopharmaceuticals... See more »
January 3, 2019endpoints news

With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators

Having selected a second immune modulator to move into the clinic eight months ago, Connect Biopharma... See more »
April 24, 2018BioPortfolio

Connect Biopharmaceuticals Advances CBP201 a Novel Monoclonal Antibody Against IL4R Into Clinical Development

TAICANG China April 24 2018 PRNewswire Connect Biopharmaceuticals Ltd. today announced that it has su... See more »

Headquarters

6 Beijing West Road 3rd Floor, Science and Technology Park, East R&D Building

Taicang, Jiangsu Province215400

0512-53577866

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Connect Biopharmaceuticals is a clinical-stage company that develops immune modulators for the treatment of autoimmune and inflammatory diseases. Connect Biopharmaceuticals was founded in 2012. Connect Biopharmaceuticals' headquarters is located in Ta...

CEO

Connect Biopharmaceuticals's Co-Founder & CEO, Zheng Wei, currently has an approval rating of 89%. Connect Biopharmaceuticals's primary competitors are Sino Biological, BeiGene & Innovent.

Website

connectbiopharm.com

Frequently Asked Questions about Connect Biopharmaceuticals

  1. When was Connect Biopharmaceuticals founded?

    Connect Biopharmaceuticals was founded in 2012
  2. Who is Connect Biopharmaceuticals's CEO?

    Connect Biopharmaceuticals's CEO is Zheng Wei
  3. How much revenue does Connect Biopharmaceuticals generate?

    Connect Biopharmaceuticals generates $5.6M in revenue
  4. How much funding does Connect Biopharmaceuticals have?

    Connect Biopharmaceuticals has historically raised $190M in funding
  1. Where is Connect Biopharmaceuticals's headquarters?

    Connect Biopharmaceuticals's headquarters is in Taicang Jiangsu Province, CN
  2. How many employees does Connect Biopharmaceuticals have?

    Connect Biopharmaceuticals has 50 employees
  3. What sector does Connect Biopharmaceuticals operate in?

    Connect Biopharmaceuticals is in Biotechnology
  4. Who are Connect Biopharmaceuticals's competitors?

    Connect Biopharmaceuticals's top competitors are Sino Biological, BeiGene, Innovent